Orchid Island Capital Inc (NYSE:ORC) had a decrease of 0.17% in short interest. ORC’s SI was 3.78M shares in December as released by FINRA. Its down 0.17% from 3.78 million shares previously. With 502,600 avg volume, 8 days are for Orchid Island Capital Inc (NYSE:ORC)’s short sellers to cover ORC’s short positions. The stock increased 0.26% or $0.01 during the last trading session, reaching $5.68. About 115,321 shares traded. Orchid Island Capital, Inc. (NYSE:ORC) has declined 13.92% since December 10, 2018 and is downtrending. It has underperformed by 13.92% the S&P500. Some Historical ORC News: 12/04/2018 – Orchid Island Capital Announces April 2018 Monthly Dividend and March 31, 2018 RMBS Portfolio Characteristics; 04/05/2018 – Resource America Inc. Exits Position in Orchid Island; 23/04/2018 – DJ Orchid Island Capital Inc, Inst Holders, 1Q 2018 (ORC); 15/05/2018 – Wolverine Asset Management Buys 1.2% Position in Orchid Island; 08/03/2018 Orchid Island Capital Announces March 2018 Monthly Dividend and February 28, 2018 RMBS Portfolio Characteristics; 26/04/2018 – Orchid Island Capital 1Q Loss/Shr 31c; 16/05/2018 – Orchid Island Capital Announces May 2018 Monthly Dividend and April 30, 2018 RMBS Portfolio Characteristics; 12/04/2018 – ORCHID ISLAND CAPITAL INC – ESTIMATED BOOK VALUE PER SHARE AT MARCH 31, 2018 OF $8.09; 12/04/2018 – ORCHID ISLAND CAPITAL INC – ESTIMATED GAAP NET LOSS OF $0.31 PER SHARE FOR QUARTER ENDED MARCH 31, 2018
The stock of bluebird bio, Inc. (NASDAQ:BLUE) is a huge mover today! The stock increased 7.73% or $5.92 during the last trading session, reaching $82.52. About 1.11M shares traded or 9.98% up from the average. bluebird bio, Inc. (NASDAQ:BLUE) has declined 27.04% since December 10, 2018 and is downtrending. It has underperformed by 27.04% the S&P500. Some Historical BLUE News: 26/04/2018 – Poseida Therapeutics Presents Clinical Manufacturing Method for Durable, Persistent CAR-T Stem Cell Memory Therapies at World O; 28/03/2018 – Bluebird whistles up a co-development/co-commercialization pact with Celgene on bb2121 CAR-T $BLUE $CELG; 17/05/2018 – bluebird bio to Present New Data from LentiGlobinTM Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease Clinica; 13/04/2018 – CRISPR Therapeutics to Present Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018; 17/05/2018 – bluebird bio to Present New Data from LentiGlobinTM Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease Clinical Studies at Annual Congress of the European Hematology Association; 17/04/2018 – Obsidian Therapeutics Presents Preclinical Data from Regulated Cytokine Programs that Enable CAR-T Therapies with Controllable Functions; 16/05/2018 – #ASCO18 $BLUE $CELG BCMA CAR-T focus likely on the 2 deaths; 23/05/2018 – Cesca Therapeutics’ Chief Technology Officer, Phil Coelho, Provides Deep Dive into the CAR-T Manufacturing Process in Cell & Gene Therapy; 16/04/2018 – Humanigen Signs Agreement With MD Anderson Cancer Center to Begin Research Investigating Lenzilumab as CAR-T Support; 13/03/2018 – GENSCRIPT BIO GETS CHINA FDA CLINICAL TRIALS OF LCAR-B38M CAR-TThe move comes after 9 months positive chart setup for the $4.60 billion company. It was reported on Dec, 10 by Barchart.com. We have $88.30 PT which if reached, will make NASDAQ:BLUE worth $322.00 million more.
More notable recent Orchid Island Capital, Inc. (NYSE:ORC) news were published by: Seekingalpha.com which released: “Orchid Island Capital: In A Coma – Seeking Alpha” on December 09, 2019, also Finance.Yahoo.com with their article: “Do Directors Own Orchid Island Capital, Inc. (NYSE:ORC) Shares? – Yahoo Finance” published on November 19, 2019, Globenewswire.com published: “Orchid Island Capital Announces November 2019 Monthly Dividend and October 31, 2019 RMBS Portfolio Characteristics – GlobeNewswire” on November 13, 2019. More interesting news about Orchid Island Capital, Inc. (NYSE:ORC) were released by: Finance.Yahoo.com and their article: “Is Orchid Island Capital, Inc. (ORC) A Good Stock To Buy? – Yahoo Finance” published on November 07, 2019 as well as Globenewswire.com‘s news article titled: “Orchid Island Capital Announces Third Quarter 2019 Results – GlobeNewswire” with publication date: October 24, 2019.
Orchid Island Capital, Inc., a specialty finance company, invests in residential mortgage-backed securities in the United States. The company has market cap of $358.00 million. The companyÂ’s RMBS are backed primarily by single-family residential mortgage loans, referred as Agency RMBS. It currently has negative earnings. The Company’s portfolio includes traditional pass-through Agency RMBS; and structured Agency RMBS, including collateralized mortgage obligations, interest only securities, inverse interest only securities, and principal only securities.
Investors sentiment increased to 1.83 in 2019 Q3. Its up 0.25, from 1.58 in 2019Q2. It improved, as 9 investors sold Orchid Island Capital, Inc. shares while 14 reduced holdings. 14 funds opened positions while 28 raised stakes. 23.80 million shares or 24.48% more from 19.12 million shares in 2019Q2 were reported. State Street Corporation invested in 1.11M shares or 0% of the stock. Catalyst Cap Advisors Ltd Liability Corporation holds 1,320 shares. Blackrock accumulated 5.88 million shares. Amer Int Gru owns 39,990 shares. Financial Bank Of America De reported 0% in Orchid Island Capital, Inc. (NYSE:ORC). Indexiq Advisors Lc owns 200,047 shares for 0.04% of their portfolio. Rhumbline Advisers reported 90,541 shares. Parametric Llc has 147,038 shares. Jpmorgan Chase And Com accumulated 20,763 shares. Nuveen Asset Mgmt Ltd Liability has invested 0% in Orchid Island Capital, Inc. (NYSE:ORC). Morgan Stanley invested in 0% or 37,671 shares. Bankshares Of Mellon holds 0% or 223,922 shares. Wolverine Asset Management Limited owns 1.08 million shares for 0.08% of their portfolio. Tower Capital Ltd Com (Trc) invested in 0% or 404 shares. Metropolitan Life Ny holds 0% or 13,832 shares in its portfolio.
Investors sentiment decreased to 0.81 in Q3 2019. Its down 0.46, from 1.27 in 2019Q2. It turned negative, as 39 investors sold bluebird bio, Inc. shares while 63 reduced holdings. 21 funds opened positions while 62 raised stakes. 61.82 million shares or 2.23% more from 60.47 million shares in 2019Q2 were reported. Aperio Grp Ltd Liability Corporation, California-based fund reported 12,150 shares. Prudential Finance Inc owns 2,340 shares for 0% of their portfolio. Ubs Asset Mgmt Americas has 410,163 shares. L And S Advsrs Incorporated accumulated 8,201 shares. 71,037 are held by Millennium Ltd Liability Company. Cubist Systematic Strategies Limited Liability Company owns 0.03% invested in bluebird bio, Inc. (NASDAQ:BLUE) for 18,936 shares. Walleye Trading Ltd Liability Company has 3,472 shares for 0% of their portfolio. Baker Bros Advsr Limited Partnership holds 0.02% or 40,000 shares in its portfolio. Oppenheimer Asset Mngmt Inc, a New York-based fund reported 5,101 shares. Great West Life Assurance Can reported 3,605 shares. International Investors holds 5.44M shares. Ws Management Lllp reported 0.1% of its portfolio in bluebird bio, Inc. (NASDAQ:BLUE). Raymond James Financial Svcs Advsrs Inc invested in 0% or 4,217 shares. Comml Bank Of Montreal Can holds 0% of its portfolio in bluebird bio, Inc. (NASDAQ:BLUE) for 9,642 shares. Century Cos reported 462,513 shares stake.
More notable recent bluebird bio, Inc. (NASDAQ:BLUE) news were published by: Nasdaq.com which released: “Is bluebird bio a Buy? – Nasdaq” on December 10, 2019, also Nasdaq.com with their article: “China’s blue-chips end lower after weak export data – Nasdaq” published on December 09, 2019, Nasdaq.com published: “Why Virgin Galactic Stock Just Jumped Another 11% – Nasdaq” on December 10, 2019. More interesting news about bluebird bio, Inc. (NASDAQ:BLUE) were released by: Nasdaq.com and their article: “Top Ranked Growth Stocks to Buy for December 10th – Nasdaq” published on December 10, 2019 as well as Nasdaq.com‘s news article titled: “United Bankshares Named Top Dividend Stock With Insider Buying and 3.71% Yield (UBSI) – Nasdaq” with publication date: December 10, 2019.
Among 7 analysts covering bluebird bio (NASDAQ:BLUE), 3 have Buy rating, 0 Sell and 4 Hold. Therefore 43% are positive. bluebird bio has $19100 highest and $8500 lowest target. $120.88’s average target is 46.49% above currents $82.52 stock price. bluebird bio had 18 analyst reports since June 17, 2019 according to SRatingsIntel. The rating was maintained by Piper Jaffray on Friday, November 1 with “Neutral”. Wells Fargo maintained the stock with “Overweight” rating in Monday, December 9 report. The stock has “Buy” rating by Maxim Group on Friday, November 1. The rating was maintained by Stifel Nicolaus with “Hold” on Friday, November 1. Morgan Stanley maintained it with “Equal-Weight” rating and $10400 target in Friday, October 11 report. On Friday, November 1 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. Evercore downgraded the stock to “In-Line” rating in Tuesday, November 19 report. The stock of bluebird bio, Inc. (NASDAQ:BLUE) earned “Outperform” rating by Leerink Swann on Tuesday, November 26. The rating was maintained by Morgan Stanley on Tuesday, August 6 with “Equal-Weight”.
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. The company has market cap of $4.60 billion. The Company’s product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. It currently has negative earnings. The companyÂ’s lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications.
Analysts await bluebird bio, Inc. (NASDAQ:BLUE) to report earnings on February, 20. They expect $-3.79 EPS, down 39.34% or $1.07 from last year’s $-2.72 per share. After $-3.73 actual EPS reported by bluebird bio, Inc. for the previous quarter, Wall Street now forecasts 1.61% negative EPS growth.